Building on this finding, a more recent study by Shueng and colleagues showed that Orlistat’s ability to inhibit FASN could address resistance to targeted drug therapy by disrupting HCC’s metabolic reprogramming [217]. Here, FASN is linked to hepatocellular carcinoma.